Drug Profile
Research programme: anti-HSV-1 meganucleases - Cellectis
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cellectis
- Class Proteins
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Herpes simplex virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in France
- 05 Apr 2011 Cellectis signs licensing agreement with undisclosed company for use of its homologous recombination technology patents and patent applications in Oncology
- 31 Mar 2010 Preclinical trials in Herpes simplex virus infections in France (unspecified route)